14.54
-0.135(-0.92%)
Currency In USD
| Previous Close | 14.67 |
| Open | 14.71 |
| Day High | 14.81 |
| Day Low | 14.35 |
| 52-Week High | 16.27 |
| 52-Week Low | 2.21 |
| Volume | 274,059 |
| Average Volume | 1.1M |
| Market Cap | 1.03B |
| PE | -3.87 |
| EPS | -3.76 |
| Moving Average 50 Days | 13.4 |
| Moving Average 200 Days | 8.89 |
| Change | -0.14 |
If you invested $1000 in Phathom Pharmaceuticals, Inc. (PHAT) since IPO date, it would be worth $590.85 as of December 04, 2025 at a share price of $14.535. Whereas If you bought $1000 worth of Phathom Pharmaceuticals, Inc. (PHAT) shares 5 years ago, it would be worth $320.65 as of December 04, 2025 at a share price of $14.535.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
GlobeNewswire Inc.
Nov 04, 2025 1:00 PM GMT
First patient dosed, with topline results expected in 2027pHalcon-EoE-201 is the first large, well-controlled clinical trial of an acid secretory treatment in EoE FLORHAM PARK, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease
GlobeNewswire Inc.
Oct 25, 2025 1:59 PM GMT
Data published in the American Journal of Gastroenterology showed rapid and sustained relief of nighttime gastroesophageal reflux disease (GERD) symptoms in patients treated with VOQUEZNA, including clinically meaningful increases in heartburn-free n
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting
GlobeNewswire Inc.
Oct 23, 2025 12:00 PM GMT
FLORHAM PARK, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced its parti